Related Experiment Video
Updated: Jul 13, 2026

10:13
Non-Destructive Evaluation of Regional Cell Density Within Tumor Aggregates Following Drug Treatment
Published on: June 21, 2022
Rituximab and dose dense chemotherapy in primary breast lymphoma
Haematologica
|July 26, 2007
Abstract:
Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity of a dose dense regimen (CEOP-14) and rituximab in 32 previously untreated female patients with PBL in early stage. There was no difference in complete response rate (87%), event free-survival (75%) and overall survival (63%) compared with historical patients.